Investigating a new approach to treat resistant hypertension.
Targeting ADAM17 maturation in resistant hypertension.
['FUNDING_R01'] · LSU HEALTH SCIENCES CENTER · NIH-11060865
This study is looking at how a protein called ADAM17 influences blood pressure in people with hard-to-treat high blood pressure, hoping to find new ways to help those who don’t respond to regular treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LSU HEALTH SCIENCES CENTER (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-11060865 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a specific protein, ADAM17, affects the regulation of blood pressure in individuals with resistant hypertension. By studying the role of ADAM17 in the shedding of another protein, ACE2, the researchers aim to uncover new mechanisms that contribute to high blood pressure. The approach involves both laboratory experiments and potential clinical applications, which could lead to innovative treatments for patients who do not respond to standard hypertension therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 55 and older who have been diagnosed with resistant hypertension.
Not a fit: Patients with well-controlled hypertension or those who do not have hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from resistant hypertension, potentially improving their blood pressure control and overall cardiovascular health.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for hypertension treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
NEW ORLEANS, UNITED STATES
- LSU HEALTH SCIENCES CENTER — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAZARTIGUES, ERIC D — LSU HEALTH SCIENCES CENTER
- Study coordinator: LAZARTIGUES, ERIC D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.